Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP)

References

• Hakeem AH, Mohamed GB, Othman MF. Retinopathy of prematurity: a study of prevalence and risk factors. Middle East Afr J Ophthalmol. 2012;19(3):289–294. doi:10.4103/0974-9233.97927.
   PubMedGoogle Scholar
• Maroufizadeh S, Almasi- Hashiani A, Omani- Samani R, Sepidarkish M. Prevalence of retinopathy of prematurity in Iran: a systematic review and meta-analysis. Int J Ophthalmol. 2017;10(8):1273–1279. doi:10.18240/ijo.2017.08.15.
   PubMed Web of Science ®Google Scholar
• Abrishami M, Maemori G-A, Boskabadi H, Yaeghobi Z, Mafi-Nejad S, Abrishami M. Incidence and risk factors of retinopathy of prematurity in Mashhad, Northeast Iran. Iran Red Crescent Med J. 2013;15(3):229–233. doi:10.5812/ircmj.
   PubMed Web of Science ®Google Scholar
• Hsieh C-J, Liu J-W, Huang J-S, Lin K-C. Refractive outcome of premature infants with or without retinopathy of prematurity at 2 years of age: A prospective controlled cohort study. Kaohsiung J Med Sci. 2012;28(4):204–211. doi:10.1016/j.kjms.2011.10.010.
   PubMed Web of Science ®Google Scholar
• Gunay M, Celik G, Gunay BO, Aktas A, Karatekin G, Ovali F. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol. 2015;78(5):300–304. doi:10.5935/0004-2749.20150079.
   PubMed Web of Science ®Google Scholar
• Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008–1015. doi:10.1016/j.ophtha.2014.12.017.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Geloneck MM. Review of effects of anti-VEGF treatment on refractive error. Eye Brain. 2016;8:135–140. doi:10.2147/EB.S99306.
   PubMed Web of Science ®Google Scholar
• O’Connor AR, Stephenson T, Johnson A, et al. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics. 2002;109(1):12. doi:10.1542/peds.109.1.12.
   PubMed Web of Science ®Google Scholar
• Quinn GE, Dobson V, Kivlin J, et al. Prevalence of myopia between 3 months and 5 12 years in preterm infants with and without retinopathy of prematurity. Ophthalmology. 1998;105(7):1292–1300. doi:10.1016/S0161-6420(98)97036-1.
   PubMed Web of Science ®Google Scholar
• Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial refractive outcomes after bevacizumab monotherapyrefractive outcomes after bevacizumab monotherapy. JAMA Ophthalmol. 2014;132(11):1327–1333. doi:10.1001/jamaophthalmol.2014.2772.
   PubMed Web of Science ®Google Scholar
• Fierson WM. American academy of pediatrics section on ophthalmology, American academy of ophthalmology, American association for pediatric ophthalmology and strabismus, American association of certified orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189–195. doi:10.1542/peds.2012-2996.
   PubMed Web of Science ®Google Scholar
• Davitt BV, Dobson V, Good WV, et al. Early treatment for retinopathy of prematurity cooperative group. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology. 2005;112(9):1564–1568. doi:10.1016/j.ophtha.2005.03.025.
   PubMed Web of Science ®Google Scholar
• Gursoy H, Basmak H, Bilgin B, Erol N, Colak E. The effects of mild-to-severe retinopathy of prematurity on the development of refractive errors and strabismus. Strabismus. 2014;22(2):68–73. doi:10.3109/09273972.2014.904899.
   PubMedGoogle Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155(6):1119–24.e1. doi:10.1016/j.ajo.2013.01.014.
   PubMed Web of Science ®Google Scholar
• Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retina. 2018;2(9):942–948. doi:10.1016/j.oret.2018.01.017.
   PubMedGoogle Scholar
• Kuo HK, Sun IT, Chung MY, Chen YH. Refractive error in patients with retinopathy of prematurity after laser photocoagulation or bevacizumab monotherapy. Ophthalmologica. 2015;234(4):211–217. doi:10.1159/000439182.
   PubMed Web of Science ®Google Scholar
• Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J Aapos. 2015;19(2):140–144. doi:10.1016/j.jaapos.2015.01.009.
   PubMed Web of Science ®Google Scholar
• Mueller B, Salchow DJ, Waffenschmidt E, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2017;101(3):365–370. doi:10.1136/bjophthalmol-2016-308375.
   PubMed Web of Science ®Google Scholar
• Larsson EK, Rydberg AC, Holmström GE. A population-based study of the refractive outcome in 10-year-old preterm and full-term children. Arch Ophthalmol. 2003;121(10):1430–1436. doi:10.1001/archopht.121.10.1430.
   PubMedGoogle Scholar
• Holmström GE, Larsson EK. Development of spherical equivalent refraction in prematurely born children during the first 10 years of life: a population-based study. Arch Ophthalmol. 2005;123(10):1404–1411. doi:10.1001/archopht.123.10.1404.
   PubMedGoogle Scholar
• Gunay M, Sekeroglu MA, Handan Bardak M, et al. Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus. 2016;24(2):84–88. doi:10.3109/09273972.2016.1159232.
   PubMed Web of Science ®Google Scholar
• Snir M, Friling R, Weinberger D, Sherf I, Axer-Siegel R. Refraction and keratometry in 40 week old premature (corrected age) and term infants. British J Ophthalmol. 2004;88(7):900. doi:10.1136/bjo.2003.037499.
   PubMed Web of Science ®Google Scholar
• Ouyang LJ, Yin ZQ, Ke N, et al. Refractive status and optical components of premature babies with or without retinopathy of prematurity at 3-4 years old. Int J Clin Exp Med. 2015;8(7):11854–11861.
   PubMed Web of Science ®Google Scholar
• Cook A, White S, Batterbury M, Clark D. Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2008;49(12):5199–5207. doi:10.1167/iovs.06-0114.
   PubMed Web of Science ®Google Scholar
• Wang J, Ren X, Shen L, Yanni SE, Leffler JN, Birch EE. Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013;54:6018–6024. doi:10.1167/iovs.13-11765.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Tsai YY. Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity. Clin Ophthalmol. 2016;10:1323–1327. doi:10.2147/OPTH.S110717.
   PubMedGoogle Scholar
• Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155(1):150–158. doi:10.1016/j.ajo.2012.06.010.
   PubMed Web of Science ®Google Scholar
• Friling R, Weinberger D, Kremer I, Avisar R, Sirota L, Snir M. Keratometry measurements in preterm and full term newborn infants. Br J Ophthalmol. 2004;88:8–10. doi:10.1136/bjo.88.1.8.
   PubMed Web of Science ®Google Scholar
• Fieß A, Schuster AK, Nickels S, et al. Association of low birth weight with myopic refractive error and lower visual acuity in adulthood: results from the population-based gutenberg health study (GHS). Br J Ophthalmol. 2018;103(1):99–105. doi:10.1136/bjophthalmol-2017-311774.
   PubMed Web of Science ®Google Scholar